Rahul Guha
Managing Director & Partner
Mumbai
Rahul joined The Boston Consulting Group in early 2005. He has worked across the Health Care and Industrial Goods practices both in India and the US. He is also a topic expert in Smart Simplicity. Rahul works on topics of organization design and strategy, particularly in the area of generics in the pharmaceuticals sector.
Rahul has extensive project experience in medtech. He is part of the CII National Committee on Medical Technology and is the lead author of the Vision 2025 report for the medtech sector in India. In his vast experience, Rahul has supported a private equity company in developing a strategy for emerging medtech markets; designed a new organizational model and redesigned the supply chain processes for an injectable genetics player; and helped a medtech company develop its Next Billion strategy for India.
In pharma, Rahul has been equally prolific. Among his many projects, he has redesigned the global organization structure and governance processes for a generics biopharma company; advised on portfolio selection and capability assessment for a branded generics business in India; and developed an oncology-integrated sales organization for a biopharma company.
Prior to joining BCG, Rahul was the cofounder of Nautilus Software and the chief technology officer of Valuepay.com, where he was responsible for product development in the US market.
Indian Pharmaceutical Industry has been a global powerhouse for supply of affordable medicines. The publication explores Future of Work Thinking Around 5 Core Operating Pillars for Manufacturing.
The Indian pharmaceutical sector has faced significant disruptions across its value chain, including the quality function, due to Covid-19. For most pharmaceutical companies, the quality function has been plagued by several challenges such as unavailability of manpower, inadequate remote working infrastructure and significant volatility in supply and demand.
This perspective provides a holistic view of key elements required to build the future commercial operating model, post COVID 19.
The past decade has been good for Indian companies, so far as top line expansion is concerned. Large Indian enterprises have achieved this phenomenal feat by setting out bold aspirations, building global business models and focusing diligently on tight execution.